

Food and Drug Administration Rockville MD 20857

July 10, 2013

FILE COPY

Joan Janulis, R.A.C. Vice President Lachman Consultant Services, Inc. 1600 Stewart Avenue Westbury, NY 11590

Re: This is a correction to the acknowledgement letter of 7/3/2013

Dear Ms. Janulis:

Your petition to the Food and Drug Administration requesting to declare that Hydrocodone Bitartrate and Acetaminophen Tablets USP, 4mg/300 mg, 6 mg/300 mg and 8 mg/300 mg are suitable for submission as an abbreviated new drug application (ANDA), was received by this office on 07/03/2013. It was assigned docket number FDA-2013-P-0813/CP1, and it was filed on 07/03/2013. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Gloria Ortega

Administrative Proceedings Officer

Division of Dockets Management

FDA/Office of the Executive Secretariat (OES)